Investor Presentaiton
Oncology
Hematology
Cell Therapy
Immunology
Cardiovascular
Reblozyl (Erythroid Maturation Agent)
Indication
Phase/Study
# of Patients
1L Myelodysplastic Syndrome (MDS)
Associated Anemia
Phase III COMMANDS
N = 362
Reblozyl 1.0 mg/kg SC Q3W
.
Design
Epoetin Alfa 450 IU/kg SC QW
Primary: RBC-TI for 12 weeks with a mean hemoglobin
increase > 1.5 g/dL through week 24
•
Endpoints
U.S. FDA approval August 2023
•
Status
Application under review in EU & Japan
Data presented at ASCO & EHA 2023
•
CT Identifier
ll Bristol Myers Squibb™ | Q3 2023 Results
NCT03682536
1L TD Myelofibrosis (MF)
Associated Anemia
Phase III INDEPENDENCE
N = 309
Reblozyl 1.33 mg/kg SC Q3W + JAK2i
Placebo SC Q3W + JAK2i
Primary: RBC-TI during any consecutive 12-week period starting
within the first 24 weeks
Key secondary: RBC-TI ≥ 16 weeks (RBC-TI 16)
Recruiting
Expected data readout 2025
NCT04717414
Not for Product Promotional Use
41View entire presentation